| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/08/2006 | WO2005103713A3 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 09/08/2006 | CA2600628A1 Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage |
| 09/08/2006 | CA2599989A1 N-phenyl benzamide derivatives as sirtuin modulators |
| 09/08/2006 | CA2599959A1 Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
| 09/08/2006 | CA2599864A1 Peptide-mimetics and use thereof as inhibitors of the 20s proteasome, 26s proteasome and the immunoproteasome |
| 09/08/2006 | CA2599718A1 Methods and pharmaceutical compositions for the treatment of neurological damage |
| 09/08/2006 | CA2599688A1 Cinnoline compounds and their use as liver x receptor modulators |
| 09/08/2006 | CA2599662A1 Use of pde7 inhibitors for the treatment of neuropathic pain |
| 09/08/2006 | CA2599588A1 Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
| 09/08/2006 | CA2599544A1 Novel aminopyridine compound with syk inhibitory activity |
| 09/08/2006 | CA2599331A1 Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals preparation comprising the same |
| 09/08/2006 | CA2598785A1 Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids |
| 09/07/2006 | US20060199978 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders |
| 09/07/2006 | US20060199957 Novel bicyclic and tricyclic cannabinoids |
| 09/07/2006 | US20060199866 Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse |
| 09/07/2006 | US20060199861 Methods of using derivatives of (-)-venlafaxine |
| 09/07/2006 | US20060199860 Salts of (-)-O-desmethylvenlafaxine |
| 09/07/2006 | US20060199842 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 09/07/2006 | US20060199841 Pharmaceutical combination for the treatment of spasticity and/or pain |
| 09/07/2006 | US20060199835 Neuroprotective and anti-proliferative compounds |
| 09/07/2006 | US20060199827 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/07/2006 | US20060199825 4-Aminating a 4-chloro-2-hydroxy-3-nitrodihydroquinoline with a N-(hetero)cyclylpiperazine, and alkylating the remaining amine group in the quinoline ring to produce a 4-(4-(hetero)cyclylpiperazinyl)-3-nitro-1-alkyldihydroquinolinone |
| 09/07/2006 | US20060199818 Inhibiting the activity of a 5-hydroxytryptamine 2A by administering a N-heterocyclyl (preferably 1,3-dioxan-5-yl)-4-[(N-substituted)(hetero)arylamino]piperidine in which the N-substituant is arylalkanoyl, arylthioalkanoyl, arylalkylaminocarbonyl or arylalkylaminothiocarbonyl group |
| 09/07/2006 | US20060199815 NK1 antagonists |
| 09/07/2006 | US20060199813 Neurodegenerative diseases, psychological disorders; e.g. 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydroquinoline |
| 09/07/2006 | US20060199810 Neurodegenerative diseases, psychological disorders; e.g. 1-[3-(4-Butyl-piperidin-1-yl)-propyl]-1,2,3,4-tetrahydro-quinoline |
| 09/07/2006 | US20060199799 Benzimidazolidinone derivatives as muscarinic agents |
| 09/07/2006 | US20060199794 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension |
| 09/07/2006 | US20060199792 Peroxynitrite decomposition catalysts and methods of use thereof |
| 09/07/2006 | US20060199790 Use of 3-methoxy-pregnenolone in the production of a medicament for treating neurodegenerative diseases |
| 09/07/2006 | US20060199787 N-(2-acetamidoethyl)phosphonoformamide; inhibiting effect on zinc-containing proteinases, inhibiting cancer cells |
| 09/07/2006 | US20060199774 Intensify nerve growth factor; using chroman compound |
| 09/07/2006 | US20060198914 Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders |
| 09/07/2006 | US20060198790 Buccal, polar and non-polar spray containing ondansetron |
| 09/07/2006 | DE19526233B4 Hydroxylierte Azabicyclooctyl-tetra- und -hexahydrobenz[d,e]isochinolone, deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten Hydroxylated Azabicyclooctyl tetra- and -hexahydrobenz [e] isochinolone, their preparation and pharmaceutical compositions containing these |
| 09/07/2006 | DE102005009909A1 Verbindungen geeignet zur Beseitigung fehlgefalteter Proteine Compounds suitable for the removal of misfolded proteins |
| 09/06/2006 | EP1698697A2 SSD-containing protein, process for producing the same and use thereof |
| 09/06/2006 | EP1698685A1 Fat composition |
| 09/06/2006 | EP1698629A2 Polyamines and their use in therapy |
| 09/06/2006 | EP1698627A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2006 | EP1698624A1 Phenylpropanoic acid derivatives |
| 09/06/2006 | EP1698622A1 Agent or method for treatment for severe aphasia in chronic-stage cerebrovascular disorder |
| 09/06/2006 | EP1698375A1 Azetidine ring compounds and drugs comprising the same |
| 09/06/2006 | EP1698340A1 T-type calcium channel inhibitor |
| 09/06/2006 | EP1698338A2 S-methyl-dihydro-ziprasidone for the treatment of schizophrenia |
| 09/06/2006 | EP1698335A1 Preventive and/or therapeutic agent for disease in which mitochondrial benzodiazepine receptor participates |
| 09/06/2006 | EP1697379A1 Spirocyclic cyclohexane derivatives |
| 09/06/2006 | EP1697378A2 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| 09/06/2006 | EP1697371A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/06/2006 | EP1697370A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 09/06/2006 | EP1697362A1 Crf receptor antagonists and methods relating thereto |
| 09/06/2006 | EP1697359A1 Muscarinic agonists as therapeutic compounds |
| 09/06/2006 | EP1697353A2 Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors |
| 09/06/2006 | EP1697332A1 Benzo'1,4 ! diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof |
| 09/06/2006 | EP1697318A1 Prolinylarylacetamides |
| 09/06/2006 | EP1697308A2 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer s disease |
| 09/06/2006 | EP1697305A1 Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists |
| 09/06/2006 | EP1697005A1 Combination of flupirtine and tramadol |
| 09/06/2006 | EP1696959A2 Melatonin combination therapy for improving sleep quality |
| 09/06/2006 | EP1696948A1 Use of relaxin as adjuvant in the differentiation of stem cells for the reconstruction of tissues |
| 09/06/2006 | EP1696931A2 Amino substituted diaryl [a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| 09/06/2006 | EP1696930A1 Tricyclic 1-((3-indol-3-yl)carbonyl)piperazine derivatives as cannabinoid cb1 receptor agonists |
| 09/06/2006 | EP1696929A2 Delta-9-thc compositions and methods for treating symptoms associated with multiple sclerosis |
| 09/06/2006 | EP1696924A1 Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies |
| 09/06/2006 | EP1696922A1 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases |
| 09/06/2006 | EP1696906A1 Novel therapeutic use of indolinone derivatives |
| 09/06/2006 | EP1696905A1 Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease |
| 09/06/2006 | EP1696904A1 Use of rotigotine for the treatment or prevention of dopaminergic neurone loss |
| 09/06/2006 | EP1696896A2 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 09/06/2006 | EP1696890A2 Coated tablet containing venlafaxin or its salts with controlled release |
| 09/06/2006 | EP1517894B1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 09/06/2006 | EP1409490B1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta a|naphthalenyl derivatives with antipsychotic activity |
| 09/06/2006 | EP1406609B1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 09/06/2006 | EP1401441A4 Allosteric adenosine receptor modulators |
| 09/06/2006 | EP1397145B1 Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders |
| 09/06/2006 | EP1383768B1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 09/06/2006 | EP1374952B1 Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| 09/06/2006 | EP1345607B1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 09/06/2006 | EP1326632B1 Proteasome inhibitors for the treatment of hepatitis virus infections |
| 09/06/2006 | EP1322383B9 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 09/06/2006 | EP1274423A4 Medicine for treating traumatic brain injury and other neuronal disorders |
| 09/06/2006 | EP1259241B8 The use of scopolamine salts |
| 09/06/2006 | EP1223933B1 5-membered heterocycle derivatives and use thereof as monoaminoxidase inhibitors |
| 09/06/2006 | EP1214350B1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 09/06/2006 | EP1003546B1 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon |
| 09/06/2006 | EP0781137B1 Use of phosphoglycerides comprising phosphoglycero ethers for treating neurodegenerative diseases in mentally severe handicapped children |
| 09/06/2006 | CN1829721A Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| 09/06/2006 | CN1829720A 7-substituted 3-nitro-pyrazolo '1,5-a! pyrimidines |
| 09/06/2006 | CN1829719A N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto |
| 09/06/2006 | CN1829703A (Thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
| 09/06/2006 | CN1829689A Benzylamine derivative |
| 09/06/2006 | CN1829522A Inhalable gaseous medicine based on xenon and nitrous oxide |
| 09/06/2006 | CN1827621A Novel derivatives and analogues of galanthamin |
| 09/06/2006 | CN1827619A Pyrimidine-5-(1H)-ketone derivative |
| 09/06/2006 | CN1827603A Novel pyrazole analogs acting on cannabinoid receptors |
| 09/06/2006 | CN1827590A Novel pregabalin crystalline form, its preparing process and pharmaceutical compositions thereof |
| 09/06/2006 | CN1827585A Non-crystalline memantine hydrochloride |
| 09/06/2006 | CN1827157A Chinese medicine for treating schizophrenia |
| 09/06/2006 | CN1827156A Consciousness-restoring tablet with pearl |
| 09/06/2006 | CN1827155A Consciousness-restoring granule with pearl |